<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640287</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01516-43</org_study_id>
    <nct_id>NCT02640287</nct_id>
  </id_info>
  <brief_title>Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia</brief_title>
  <acronym>WAL-KU</acronym>
  <official_title>Expression of Ku70/XRCC6 and Others NHEJ Components in Waldenström's Macroglobulinemia in Comparison With Others B-cell Lymphoproliferative Disorders and Normal B Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Waldenström's macroglobulinemia is a rare disease whose pathophysiology remains at present&#xD;
      poorly understood, although a recurrent mutation (L265P MYD88) has recently been described.&#xD;
      Unlike other lymphoproliferative disorders, there is a defect in isotype switching, mechanism&#xD;
      involving AID and NHEJ complex. Using a two-dimensional electrophoresis technology, our group&#xD;
      showed that MW had a specific proteomic profile, and one of the differentially expressed&#xD;
      proteins is Ku70 (encoded by XRCC6 belonging to NHEJ complex) .&#xD;
&#xD;
      The investigators purpose to explore the mechanisms of underexpression of Ku70/XRCC6 (genetic&#xD;
      or epigenetic modification) in comparison with other lymphoid malignancies and normal B&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of ratio Ku70/XRCC6</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparing the average level of expression of Ku70 in B cells measured in patients of WM, in patients other SLP and in healthy subjects (without MW and other SLP) , matched for age ( +/- 5 years) and sex</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Waldenström macroglobulinemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diagnosis of Waldenström macroglobulinemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Others B-cell malignancies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control healthy subjects without B-cell malignancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood or bone marrow samples</intervention_name>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Others B-cell malignancies</arm_group_label>
    <arm_group_label>Waldenström macroglobulinemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years, affiliated to the social regimen&#xD;
&#xD;
          -  Written consent collected&#xD;
&#xD;
        MW group :&#xD;
&#xD;
          -  Patient with a diagnosis of MW according to WHO criteria (based on the results of&#xD;
             serum protein electrophoresis, bone marrow analysis with immunophenotyping,&#xD;
             cytogenetic analysis and mutation L265P MyD88)&#xD;
&#xD;
        Other SLP :&#xD;
&#xD;
          -  Patient with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma&#xD;
             or Multiple Myeloma&#xD;
&#xD;
        Healthy volunteers :&#xD;
&#xD;
          -  volunteers without blood disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing age who do not have an effective means of contraception&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Demonstration of a kappa or lambda monotype on B lymphocytes&#xD;
&#xD;
          -  healthy volunteer with B-cell malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Aurore PERROT</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

